|Bid||0.00 x 1400|
|Ask||0.00 x 800|
|Day's range||729.86 - 729.86|
|52-week range||515.00 - 818.60|
|Beta (5Y monthly)||0.89|
|PE ratio (TTM)||5.37|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
HERCULES, Calif., October 15, 2021--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, will report financial results for the third quarter 2021 on Thursday, October 28, 2021, following the close of the market. The company will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day.
Bio Rad (BIO) is witnessing strong growth in the biopharma market, riding on the Droplet Digital PCR platform.
Bio-Rad (BIO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.